University of Dundee

Medical Research Council Protein Phosphorylation and Ubiquitylation Unit

Short Code: 

50 years of Protein Phosphorylation

On October 1st 1969 Philip Cohen became a postdoc in Edmond Fischer’s at the University of Washington, Seattle, USA and started his research on protein phosphorylation.

At that time only three protein kinases had been identified and protein phosphorylation was thought-to-be a specialised control mechanism confined to the regulation of glycogen metabolism.

‘Tête-à-tête: The p97-UBXD8 complex regulates ER-mitochondrial contact sites’

Malavika (Mali) Raman is originally from Chennai India. She earned her undergraduate degree in Biology and Pharmacy at the Birla Institute of Technology and Science in Rajasthan India. In 2001 she joined the laboratory of Melanie H. Cobb in the Department of Pharmacology at the University of Texas Southwestern Medical Center in Dallas, Texas. Her graduate thesis work involved characterizing TAO kinases, a poorly understood family of MAP3-Kinases that regulated p38 MAPK.

Development of a selective PROTAC compound by Alessi and Ciulli labs

Hannah Tovell a PhD student in Dario Alessi lab working in collaboration with Claire Crafter (AstraZeneca) and Alessio Ciulli and Andrea Testa in his lab have elaborated a compound that we have termed SGK3-PROTAC1 that induces selective degradation of SGK3 protein kinase.

Hannah was able to show that SGK3-PROTAC1 suppressed proliferation of ZR-75-1 and CAMA-1 cancer cell lines treated with a PI3K inhibitor (GDC0941) more effectively than could be achieved by a conventional SGK isoform inhibitor (14H), underscoring the benefit of the PROTAC approach.